EP1765403A4 - Combined active and passive targeting of biologically active agents - Google Patents
Combined active and passive targeting of biologically active agentsInfo
- Publication number
- EP1765403A4 EP1765403A4 EP05780057A EP05780057A EP1765403A4 EP 1765403 A4 EP1765403 A4 EP 1765403A4 EP 05780057 A EP05780057 A EP 05780057A EP 05780057 A EP05780057 A EP 05780057A EP 1765403 A4 EP1765403 A4 EP 1765403A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- passive targeting
- combined
- biologically active
- active
- active agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56977004P | 2004-05-10 | 2004-05-10 | |
PCT/US2005/015681 WO2005115457A2 (en) | 2004-05-10 | 2005-05-05 | Combined active and passive targeting of biologically active agents |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1765403A2 EP1765403A2 (en) | 2007-03-28 |
EP1765403A4 true EP1765403A4 (en) | 2011-03-30 |
Family
ID=35451414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05780057A Withdrawn EP1765403A4 (en) | 2004-05-10 | 2005-05-05 | Combined active and passive targeting of biologically active agents |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1765403A4 (en) |
WO (1) | WO2005115457A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103458911B (en) | 2011-02-11 | 2016-02-24 | 密歇根大学董事会 | Peptide combinations and the method being used for the treatment of patient |
CN111454302B (en) * | 2020-04-30 | 2022-07-05 | 大连理工大学 | Chlorin e6 ferrocene conjugate with light and sound sensitive activity, preparation method and application |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5853713A (en) * | 1994-02-28 | 1998-12-29 | Sterling Winthrop Inc. | Biologically compatible linear block copolymers of polyalkylene oxide and peptide units |
WO1999029303A1 (en) * | 1997-12-12 | 1999-06-17 | Samyang Corporation | Biodegradable mixed polymeric micelles for gene delivery |
WO2001091798A2 (en) * | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
US20020099041A1 (en) * | 2000-10-06 | 2002-07-25 | Gallop Mark A. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
WO2003046185A1 (en) * | 2001-11-28 | 2003-06-05 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
WO2003070982A1 (en) * | 2002-02-22 | 2003-08-28 | Avaris Ab | Complex comprising at least two biospecific elements separated by a nucleic acid linker e.g. for identification of drug delivery candidates. combinatorial library of such complexes |
WO2004009136A2 (en) * | 2002-07-22 | 2004-01-29 | Psimei Pharmaceuticals Plc | Conjugates of n-hydroxypropymethacrylamide-methacrylate copolymer with nuclide activation agent and/or anti-cancer compounds |
-
2005
- 2005-05-05 WO PCT/US2005/015681 patent/WO2005115457A2/en active Application Filing
- 2005-05-05 EP EP05780057A patent/EP1765403A4/en not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5853713A (en) * | 1994-02-28 | 1998-12-29 | Sterling Winthrop Inc. | Biologically compatible linear block copolymers of polyalkylene oxide and peptide units |
WO1999029303A1 (en) * | 1997-12-12 | 1999-06-17 | Samyang Corporation | Biodegradable mixed polymeric micelles for gene delivery |
WO2001091798A2 (en) * | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
US20020099041A1 (en) * | 2000-10-06 | 2002-07-25 | Gallop Mark A. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
WO2003046185A1 (en) * | 2001-11-28 | 2003-06-05 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
WO2003070982A1 (en) * | 2002-02-22 | 2003-08-28 | Avaris Ab | Complex comprising at least two biospecific elements separated by a nucleic acid linker e.g. for identification of drug delivery candidates. combinatorial library of such complexes |
WO2004009136A2 (en) * | 2002-07-22 | 2004-01-29 | Psimei Pharmaceuticals Plc | Conjugates of n-hydroxypropymethacrylamide-methacrylate copolymer with nuclide activation agent and/or anti-cancer compounds |
Also Published As
Publication number | Publication date |
---|---|
WO2005115457A3 (en) | 2009-04-09 |
EP1765403A2 (en) | 2007-03-28 |
WO2005115457A2 (en) | 2005-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1635876A4 (en) | Improved intra-dermal delivery of biologically active agents | |
IL183252A0 (en) | Solid formulations of liquid biologically active agents | |
EP1740197A4 (en) | Therapeutic enzyme formulations and uses thereof | |
IL178595A0 (en) | 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents | |
PL2213168T3 (en) | Pesticidal combination of active agents | |
IL177098A0 (en) | Controlled and sustained delivery of nucleic acid based therapeutic agents | |
GB0522503D0 (en) | Integration of micro-electro mechanical systems and active circuitry | |
IL170454A (en) | Transdermal or transmucosal formulations of active agents and uses thereof | |
ZA200600099B (en) | Active agents combination exhibiting insecticidal and acaricide properties | |
IL180887A0 (en) | Quinoline derivatives and insecticide comprising thereof as active ingredient | |
IL181801A0 (en) | Transdermal delivery of hydrophobic bioactive agents | |
PL1715743T3 (en) | Combinations of insecticide active agents based on thiacloprid and pyrethroids | |
DE602005021918D1 (en) | FINAL BODY AND TREADMILL | |
GB0524958D0 (en) | Transdermal administration of active agents | |
EP2099441A4 (en) | Metal delivery agents and therapeutic uses of the same | |
EP1758605A4 (en) | Prouroguanylin as therapeutic and diagnostic agents | |
EP1781685A4 (en) | Therapeutic and diagnostic agents | |
GB0509749D0 (en) | A method of delivering a biologically active agent | |
ZA200600098B (en) | Active agents combination exhibiting insecticidal and acaricide properties | |
HK1109581A1 (en) | Pharmaceutical use of graptopetalum and related plants | |
IL181300A0 (en) | Photosensitizer formulations and uses thereof | |
EP1667656A4 (en) | Compositions and methods for delivery of biologically active agents | |
EP1765403A4 (en) | Combined active and passive targeting of biologically active agents | |
IL179791A0 (en) | Pyridinylisoxazoles and their use as herbicides | |
EP1701736A4 (en) | Therapeutic agents and uses therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20061204 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR LV MK YU |
|
DAX | Request for extension of the european patent (deleted) | ||
PUAK | Availability of information related to the publication of the international search report |
Free format text: ORIGINAL CODE: 0009015 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/00 20060101ALI20090709BHEP Ipc: C07K 14/00 20060101AFI20090709BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20110228 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/48 20060101ALI20110222BHEP Ipc: C07K 16/00 20060101ALI20110222BHEP Ipc: C07K 14/00 20060101AFI20090709BHEP |
|
17Q | First examination report despatched |
Effective date: 20110620 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20150204 |